Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRAM Study: SBRT vs Conventional IMRT in High Risk Prostate Cancer
NCT03938649Phase 2Active, not recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- May 2019
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Acute toxicities at 4 years. Started May 2019; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03938649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938649.